The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL HL Update 2021 | Inferior outcomes seen in elderly patients with HL
Jonathan Friedberg
• 11 Mar 2021
Jonathan Friedberg, MD, University of Rochester, Rochester, NY, explores why elderly patients with Hodgkin lymphoma (HL) demonstrate inferior outcomes, including comorbidities that limit the ability to give standard treatment, as well as the complex form of Hodgkin lymphoma seen in older patients. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
